This issue of Heart Failure Clinics examines the pharmacologic approaches to heart failure: optimizing established therapy with a look toward future agents. Topics include the pathophysiologic foundation for the pharmacologic treatment of heart failure, treatment of heart failure with reducted ejection fraction and preserved ejection fraction, treatment of acute heart failure, investigational treatments, and the role of congestive heart failure medications following left ventricular assist device.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. HEART FAILURE CLINICS - p. 5 6. Foreword: Pharmacotherapy for Heart Failure: The More We Get to Know, the More We Need to Know - p. 6 7. Time and Technology Will Tell - p. 7 8. Mineralcorticoid Antagonists in Heart Failure - p. 19 9. Current Perspectives on Hydralazine and Nitrate Therapies in Heart Failure - p. 23 10. Polypharmacy in Heart Failure - p. 32 11. Management Strategies for Heart Failure with Preserved Ejection Fraction - p. 43 12. Potential Applications of Pharmacogenomics to Heart Failure Therapies - p. 49 13. Potential Roles of Vaptans in Heart Failure - p. 56 14. Lipid-Modifying Treatments for Heart Failure - p. 66 15. Current Approaches to Antiarrhythmic Therapy in Heart Failure - p. 74 16. The Role of Heart Failure Pharmacotherapy After Left Ventricular Assist Device Support - p. 82 17. Index - p. 88
No hay muestra disponible
No hay ficha técnica disponible
This issue of Heart Failure Clinics examines the pharmacologic approaches to heart failure: optimizing established therapy with a look toward future agents. Topics include the pathophysiologic foundation for the pharmacologic treatment of heart failure, treatment of heart failure with reducted ejection fraction and preserved ejection fraction, treatment of acute heart failure, investigational treatments, and the role of congestive heart failure medications following left ventricular assist device.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. HEART FAILURE CLINICS - p. 5 6. Foreword: Pharmacotherapy for Heart Failure: The More We Get to Know, the More We Need to Know - p. 6 7. Time and Technology Will Tell - p. 7 8. Mineralcorticoid Antagonists in Heart Failure - p. 19 9. Current Perspectives on Hydralazine and Nitrate Therapies in Heart Failure - p. 23 10. Polypharmacy in Heart Failure - p. 32 11. Management Strategies for Heart Failure with Preserved Ejection Fraction - p. 43 12. Potential Applications of Pharmacogenomics to Heart Failure Therapies - p. 49 13. Potential Roles of Vaptans in Heart Failure - p. 56 14. Lipid-Modifying Treatments for Heart Failure - p. 66 15. Current Approaches to Antiarrhythmic Therapy in Heart Failure - p. 74 16. The Role of Heart Failure Pharmacotherapy After Left Ventricular Assist Device Support - p. 82 17. Index - p. 88
No hay muestra disponible
No hay ficha técnica disponible
